Imugene kicks off IND process for HER-Vaxx
18 March, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx.
Biomedical Research Victoria
18 March, 2014Melbourne's Bio21 Cluster has transitioned into Biomedical Research Victoria, a new statewide biomedical research group.
Starpharma's VivaGel condoms approved in Japan
17 March, 2014 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) marketing partner Okamoto Industries has won regulatory approval to market VivaGel-coated condoms in Japan.
Calzada appoints new chairman
17 March, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) newest director, David Williams, has been chosen to replace Roger Aston as board chairman.
Viralytics closes $27m capital raising
14 March, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) said a recent $27.1m placement and entitlement offer has left it with enough cash to fund its cancer trial programs through 2016.
Bionomics, CEO win industry awards
13 March, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has been named Innovative Asian Biotech of the Year, and CEO Deborah Rathjen Life Science Woman Executive of the Year, at the BioPharma Asia Industry Awards.
GTG breast cancer test found to be cost-effective
12 March, 2014 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) said economic modelling has shown the cost-effectiveness of using BREVAGen to help direct chemoprevention to women at elevated risk of breast cancer.
Starpharma gets $4.7m R&D tax incentive
11 March, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has been allocated its $4.7m R&D tax incentive rebate on its FY13 expenditures, and revealed it ended 1H14 in a cash position of $27.8m.
Autism cooperative research receives support
11 March, 2014The new Cooperative Research Centre for Living with Autism Spectrum Disorders will receive $31 million in Commonwealth funding over the next eight years.
Regeneus's Kvax featured in cancer journal
07 March, 2014 by Dylan Bushell-EmblingA peer reviewed article about Regeneus's (ASX:RGS) Kvax, a canine cancer vaccine with potential human applications, has been published in Cancer Immunology Research.
Biotron shares surge 123% on HIV/HCV trial data
07 March, 2014 by Dylan Bushell-EmblingBiotron (ASX:BIT) has announced promising additional early results from a trial of BIT225 in patients with both HIV and HCV.
Viralytics kicks off STORM cancer trial
06 March, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has commenced a clinical trial involving delivering multiple intravenous doses of Cavatak to treat late-stage melanoma, prostate, lung and metastatic bladder cancers.
Alchemia licenses CTx cancer drug candidates
06 March, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) will in-license two early-stage cancer drug candidates originating from CTx research.
In-transition Novogen names new directors
05 March, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has named two new directors, including the lead inventor of its new ATM cancer drug platform, and revealed it swung to a 1H14 loss.
New theory on type 2 diabetes
04 March, 2014Nobel laureate Dr James D Watson has released a new hypothesis on the causation of type 2 diabetes.
